newsfilter
← Latest News
PR Newswire·

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

LEXINGTON, Mass., July 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced the d